Acquired QT interval prolongation and HERG: implications for drug discovery and development.
暂无分享,去创建一个
John Sharkey | Harry J Witchel | J. Mcculloch | H. Witchel | James McCulloch | K. Finlayson | J. Sharkey | Keith Finlayson
[1] Ward Oc. A NEW FAMILIAL CARDIAC SYNDROME IN CHILDREN. , 1964 .
[2] M. Sanguinetti,et al. A mechanistic link between an inherited and an acquird cardiac arrthytmia: HERG encodes the IKr potassium channel , 1995, Cell.
[3] Charles Antzelevitch,et al. Assessing predictors of drug-induced torsade de pointes. , 2003, Trends in pharmacological sciences.
[4] J. Vandenbroucke,et al. QT Interval Prolongation Predicts Cardiovascular Mortality in an Apparently Healthy Population , 1991, Circulation.
[5] Hua-rong Lu,et al. In vivo measurement of QT prolongation, dispersion and arrhythmogenesis: application to the preclinical cardiovascular safety pharmacology of a new chemical entity , 2002, Fundamental & clinical pharmacology.
[6] Wataru Shimizu,et al. Cellular mechanisms underlying the long QT syndrome. , 2002, Current opinion in cardiology.
[7] Jun Zhou,et al. Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics. , 2002, The Journal of pharmacology and experimental therapeutics.
[8] J. Miller,et al. Low-level exercise testing after myocardial infarction: usefulness in enhancing clinical risk stratification. , 1985, Circulation.
[9] Todd Wisialowski,et al. Differential effect of HERG blocking agents on cardiac electrical alternans in the guinea pig. , 2004, European journal of pharmacology.
[10] W. F. Hoffman,et al. Optimization of the indolyl quinolinone class of KDR (VEGFR-2) kinase inhibitors: effects of 5-amido- and 5-sulphonamido-indolyl groups on pharmacokinetics and hERG binding. , 2004, Bioorganic & medicinal chemistry letters.
[11] J. M. Di Diego,et al. Cisapride-Induced Transmural Dispersion of Repolarization and Torsade de Pointes in the Canine Left Ventricular Wedge Preparation During Epicardial Stimulation , 2003, Circulation.
[12] P. Davey. Influence of posture and handgrip on the QT interval in left ventricular hypertrophy and in chronic heart failure. , 1999, Clinical science.
[13] Robert Pearlstein,et al. Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior. , 2003, Journal of medicinal chemistry.
[14] T. Garyantes,et al. Development and Evaluation of High Throughput Functional Assay Methods for hERG Potassium Channel , 2001, Journal of biomolecular screening.
[15] S. Lipsius,et al. Effects of extracellular Mg2+ on T- and L-type Ca2+ currents in single atrial myocytes. , 1990, The American journal of physiology.
[16] M. Arsenian. Magnesium and cardiovascular disease. , 1993, Progress in cardiovascular diseases.
[17] Jules C Hancox,et al. Inhibitory actions of the selective serotonin re‐uptake inhibitor citalopram on HERG and ventricular L‐type calcium currents , 2002, FEBS letters.
[18] Marc A. Vos,et al. Electrophysiological Safety of Sertindole in Dogs with Normal and Remodeled Hearts , 2003, Journal of Pharmacology and Experimental Therapeutics.
[19] Paul B Bennett,et al. Trends in ion channel drug discovery: advances in screening technologies. , 2003, Trends in biotechnology.
[20] W. Crumb,et al. Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. , 2002, The Journal of pharmacology and experimental therapeutics.
[21] J. Weiss,et al. Diurnal pattern of QTc interval: how long is prolonged? Possible relation to circadian triggers of cardiovascular events. , 1996, Journal of the American College of Cardiology.
[22] Y. Jan,et al. Molecular studies of voltage-gated potassium channels. , 1990, Cold Spring Harbor symposia on quantitative biology.
[23] G. Duker,et al. Instability and Triangulation of the Action Potential Predict Serious Proarrhythmia, but Action Potential Duration Prolongation Is Antiarrhythmic , 2001, Circulation.
[24] Maurizio Recanatini,et al. Safety of Non-Antiarrhythmic Drugs that Prolong the QT Interval or Induce Torsade de Pointes , 2002, Drug safety.
[25] E. Grishin,et al. A radiolabeled peptide ligand of the hERG channel, [125I]-BeKm-1 , 2003, Pflügers Archiv.
[26] M. Sanguinetti,et al. Coassembly of KVLQT1 and minK (IsK) proteins to form cardiac IKS potassium channel , 1996, Nature.
[27] T J Campbell,et al. HERG K+ channels: friend and foe. , 2001, Trends in pharmacological sciences.
[28] A. Moss,et al. The Long QT Syndrome: Prospective Longitudinal Study of 328 Families , 1991, Circulation.
[29] Jacques Barhanin,et al. KvLQT1 and IsK (minK) proteins associate to form the IKS cardiac potassium current , 1996, Nature.
[30] Cavero,et al. QT interval prolongation by non-cardiovascular drugs: issues and solutions for novel drug development. , 1999, Pharmaceutical science & technology today.
[31] K. Finlayson,et al. A High-Throughput Binding Assay for HERG , 2004 .
[32] R. Gilmour. A novel approach to identifying antiarrhythmic drug targets. , 2003, Drug discovery today.
[33] A J Camm,et al. Evaluation of Drug-Induced QT Interval Prolongation , 2001, Drug safety.
[34] J. Mitcheson,et al. Molecular determinants of high-affinity drug binding to HERG channels. , 2003, Current opinion in drug discovery & development.
[35] R. MacKinnon. Determination of the subunit stoichiometry of a voltage-activated potassium channel , 1991, Nature.
[36] M. Sanguinetti,et al. Role of delayed rectifier potassium channels in cardiac repolarization and arrhythmias , 1997 .
[37] M. Keating,et al. MiRP1 Forms IKr Potassium Channels with HERG and Is Associated with Cardiac Arrhythmia , 1999, Cell.
[38] S. O’Donoghue,et al. Levofloxacin Induced Polymorphic Ventricular Tachycardia with Normal QT Interval , 2001, Pacing and clinical electrophysiology : PACE.
[39] A. S. Davis. The pre-clinical assessment of QT interval prolongation: a comparison of in vitro and in vivo methods , 1998, Human & experimental toxicology.
[40] Andreas Ebneth,et al. HTS techniques to investigate the potential effects of compounds on cardiac ion channels at early-stages of drug discovery. , 2003, Current opinion in drug discovery & development.
[41] C. Romano. CONGENITAL CARDIAC ARRHYTHMIA. , 1965, Lancet.
[42] J. Warmke,et al. A family of potassium channel genes related to eag in Drosophila and mammals. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[43] B. Halmos,et al. Interpopulation effect of ACE I/D polymorphism on serum concentration of ACE in diagnosis of sarcoidosis , 1997, The Lancet.
[44] O. Pongs,et al. Screening lead compounds for QT interval prolongation. , 2001, Drug discovery today.
[45] Y. Jan,et al. Cloning of genomic and complementary DNA from Shaker, a putative potassium channel gene from Drosophila. , 1987, Science.
[46] Hua-rong Lu,et al. Detection of Proarrhythmia in the Female Rabbit Heart: , 2003, Journal of cardiovascular electrophysiology.
[47] M. Jiang,et al. Mapping the Binding Site of a Humanether-a-go-go-related Gene-specific Peptide Toxin (ErgTx) to the Channel's Outer Vestibule* , 2002, The Journal of Biological Chemistry.
[48] E. Green,et al. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome , 1995, Cell.
[49] Steven L. Cohen,et al. DEPARTMENT OF PHYSIOLOGY: 2016/2017 LT/LE ORGANIZATION CHART , 2016 .
[50] G. Breithardt,et al. Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients , 2004, Journal of Molecular Medicine.
[51] Gisbert Schneider,et al. A Virtual Screening Method for Prediction of the hERG Potassium Channel Liability of Compound Libraries , 2002, Chembiochem : a European journal of chemical biology.
[52] G. Landes,et al. Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias , 1996, Nature Genetics.
[53] J. Hancox,et al. Preferential closed channel blockade of HERG potassium currents by chemically synthesised BeKm‐1 scorpion toxin , 2003, FEBS letters.
[54] A. Cavalli,et al. Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers. , 2002, Journal of medicinal chemistry.
[55] J. Henry. Epidemiology and Relative Toxicity of Antidepressant Drugs in Overdose , 1997, Drug safety.
[56] H. DeBlock,et al. Effect of short- and long-duration spaceflight on QTc intervals in healthy astronauts. , 2003, The American journal of cardiology.
[57] A. Mangoni,et al. Impact of age on QT interval and QT dispersion in healthy subjects: a regression analysis. , 2003, Age and ageing.
[58] P. Hoffmann,et al. Blinded Test in Isolated Female Rabbit Heart Reliably Identifies Action Potential Duration Prolongation and Proarrhythmic Drugs: Importance of Triangulation, Reverse Use Dependence, and Instability , 2003, Journal of cardiovascular pharmacology.
[59] Calum A. MacRae,et al. Drugs That Induce Repolarization Abnormalities Cause Bradycardia in Zebrafish , 2003, Circulation.
[60] Rita R. Patel,et al. A High-Throughput HERG Potassium Channel Function Assay: An Old Assay with a New Look , 2002, Drug development and industrial pharmacy.
[61] J. Valentin,et al. The application of in vitro methods to safety pharmacology , 2002, Fundamental & clinical pharmacology.
[62] P. Puddu,et al. Screening for drug-induced (acquired) long QT syndrome: is it time to apply new methods? , 2001, European heart journal.
[63] M. Sanguinetti,et al. Mutations in the hminK gene cause long QT syndrome and suppress lKs function , 1997, Nature Genetics.
[64] P. C. Viswanathan,et al. Allelic Variants in Long-QT Disease Genes in Patients With Drug-Associated Torsades de Pointes , 2002, Circulation.
[65] A. Camm,et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. , 2003, Cardiovascular research.
[66] S. Heinemann,et al. Molecular determinants for activation and inactivation of HERG, a human inward rectifier potassium channel. , 1996, The Journal of physiology.
[67] B. Darpö,et al. Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes , 2001 .
[68] F. Ponti,et al. QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience , 2000, European Journal of Clinical Pharmacology.
[69] D. Nutt,et al. Psychotropic Drugs, Cardiac Arrhythmia, and Sudden Death , 2003, Journal of clinical psychopharmacology.
[70] Harry J. Witchel,et al. Time course and voltage dependence of expressed HERG current compared with native ”rapid” delayed rectifier K current during the cardiac ventricular action potential , 1998, Pflügers Archiv.
[71] K. Olejniczak,et al. ICH Topic: The draft ICH S7B step 2: Note for guidance on safety pharmacology studies for human pharmaceuticals , 2002, Fundamental & clinical pharmacology.
[72] D. Mcnamara,et al. Heritable Q‐T Prolongation Without Deafness , 1970, Circulation.
[73] J. Hancox,et al. Antiarrhythmics—from cell to clinic: past, present, and future , 2000, Heart.
[74] C Antzelevitch,et al. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. , 2000, European heart journal.
[75] Paul B Bennett,et al. High throughput ion-channel pharmacology: planar-array-based voltage clamp. , 2003, Assay and drug development technologies.
[76] M. Lazdunski,et al. APETx1, a new toxin from the sea anemone Anthopleura elegantissima, blocks voltage-gated human ether-a-go-go-related gene potassium channels. , 2003, Molecular pharmacology.
[77] Jun Chen,et al. A structural basis for drug-induced long QT syndrome. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[78] C. January,et al. [3H]dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen. , 2001, European journal of pharmacology.
[79] M. Leppert,et al. The spectrum of symptoms and QT intervals in carriers of the gene for the long-QT syndrome. , 1992, The New England journal of medicine.
[80] Clay W Scott,et al. A medium-throughput functional assay of KCNQ2 potassium channels using rubidium efflux and atomic absorption spectrometry. , 2003, Analytical biochemistry.
[81] F Dessertenne,et al. [Ventricular tachycardia with 2 variable opposing foci]. , 1966, Archives des maladies du coeur et des vaisseaux.
[82] A. J. Pennington,et al. [3H]dofetilide binding in SHSY5Y and HEK293 cells expressing a HERG-like K+ channel? , 2001, European journal of pharmacology.
[83] D. Roden,et al. Drug Block of I Kr : Model Systems and Relevance to Human Arrhythmias , 2001, Journal of cardiovascular pharmacology.
[84] R. Lukas,et al. Some methods for studies of nicotinic acetylcholine receptor pharmacology , 2001 .
[85] A. Jervell,et al. Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval, and sudden death , 1957 .
[86] R. Young,et al. Optimization of a tertiary alcohol series of phosphodiesterase-4 (PDE4) inhibitors: structure-activity relationship related to PDE4 inhibition and human ether-a-go-go related gene potassium channel binding affinity. , 2003, Journal of medicinal chemistry.
[87] G. Keserü. Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods. , 2003, Bioorganic & medicinal chemistry letters.
[88] Jules C Hancox,et al. Troubleshooting problems with in vitro screening of drugs for QT interval prolongation using HERG K+ channels expressed in mammalian cell lines and Xenopus oocytes. , 2002, Journal of pharmacological and toxicological methods.
[89] G. Gintant,et al. Tissue and species distribution of mRNA for the IKr-like K+ channel, erg. , 1997, Circulation research.
[90] G. Terstappen,et al. Functional analysis of native and recombinant ion channels using a high-capacity nonradioactive rubidium efflux assay. , 1999, Analytical biochemistry.
[91] M. Gralinski. The Dog's Role in the Preclinical Assessment of QT Interval Prolongation , 2003, Toxicologic pathology.
[92] M. Chung,et al. Mechanisms by which SCN5A mutation N1325S causes cardiac arrhythmias and sudden death in vivo. , 2004, Cardiovascular research.
[93] Youxing Jiang,et al. The open pore conformation of potassium channels , 2002, Nature.
[94] Soo Sen Lee,et al. Flux assays in high throughput screening of ion channels in drug discovery. , 2003, Assay and drug development technologies.
[95] A. Moss,et al. The long QT syndrome: a prospective international study. , 1985, Circulation.
[96] Hao Wang,et al. Functional and pharmacological properties of canine ERG potassium channels. , 2003, American journal of physiology. Heart and circulatory physiology.
[97] J. Barlow,et al. CONGENITAL CARDIAC ARRHYTHMIA , 1964 .
[98] Rory Curtis,et al. A Novel Membrane Potential-Sensitive Fluorescent Dye Improves Cell-Based Assays for Ion Channels , 2002, Journal of biomolecular screening.
[99] B. Fermini,et al. The impact of drug-induced QT interval prolongation on drug discovery and development , 2003, Nature Reviews Drug Discovery.
[100] Derek Leishman,et al. Towards a drug concentration effect relationship for QT prolongation and torsades de pointes. , 2002, Current opinion in drug discovery & development.
[101] Arthur J Moss,et al. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome , 1995, Cell.
[102] C. January,et al. Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. , 1998, Biophysical journal.
[103] Joel Morganroth,et al. A definitive or thorough phase 1 QT ECG trial as a requirement for drug safety assessment. , 2004, Journal of electrocardiology.
[104] G. Breithardt,et al. Experimental models of torsade de pointes. , 1998, Cardiovascular research.
[105] B. Chait,et al. The structure of the potassium channel: molecular basis of K+ conduction and selectivity. , 1998, Science.
[106] R. Shah,et al. The significance of QT interval in drug development. , 2002, British journal of clinical pharmacology.